VKTX
Viking Therapeutics, Inc.
Overview
Viking Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $3.76B market cap.
Most recent reported earnings: Q2 FY2026 (Jul 28, 2026).
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2025Earnings2026-02-1116 Q&A exchanges
- Q3 FY2025Earnings2025-10-2223 Q&A exchanges
- Q2 FY2025Earnings2025-07-2328 Q&A exchanges
- Q4 FY2024Earnings2025-02-0537 Q&A exchanges
- Q3 FY2024Earnings2024-10-2336 Q&A exchanges
- Q2 FY2024Earnings2024-07-2428 Q&A exchanges
- Q1 FY2024Earnings2024-04-2422 Q&A exchanges
- Q4 FY2023Earnings2024-02-0729 Q&A exchanges
- Q3 FY2023Earnings2023-10-2532 Q&A exchanges
- Q2 FY2023Earnings2023-07-2628 Q&A exchanges
- Q1 FY2023Earnings2023-04-2634 Q&A exchanges
- Q4 FY2022Earnings2023-02-0832 Q&A exchanges
- Q3 FY2022Earnings2022-10-2625 Q&A exchanges
- Q2 FY2022Earnings2022-07-2730 Q&A exchanges
- Q1 FY2022Earnings2022-04-2727 Q&A exchanges
- Q4 FY2021Earnings2022-02-0928 Q&A exchanges
- Q3 FY2021Earnings2021-11-0322 Q&A exchanges
- Q2 FY2021Earnings2021-07-2832 Q&A exchanges
- Q1 FY2021Earnings2021-04-2828 Q&A exchanges
History
Earnings history
- Q2 FY20262026-07-28EPS— vs $-1.23—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-28 | — | $-1.23 | — | — | — | — | EODHD |
Source: EODHD. VKTX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks VKTX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 4/10 quarters with 30% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Missed in 2 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $2.34 | $2.53 | -7.4% | +5.9% | +6.5% |
| Q4 FY2025 | $2.34 | $2.29 | +2.3% | +6.4% | +9.2% |
| Q3 FY2025 | $2.43 | $2.51 | -3.0% | -1.9% | -4.6% |
| Q2 FY2025 | $2.57 | $2.54 | +1.1% | -4.4% | -3.2% |
| Q1 FY2024 | $2.71 | $2.58 | +4.9% | +0.9% | +3.2% |
| Q4 FY2024 | $2.47 | $2.55 | -3.0% | -4.5% | -2.2% |
| Q3 FY2024 | $2.24 | $2.41 | -7.0% | -1.6% | -3.3% |
| Q2 FY2024 | $2.27 | $2.43 | -6.6% | -2.1% | -0.8% |
| Q1 FY2023 | $2.76 | $2.57 | +7.2% | -1.6% | -2.6% |
| Q4 FY2023 | $2.45 | $2.62 | -6.6% | -0.1% | -1.0% |
Guidance change history
Sample- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Maintained2025-13-15
- Q3 FY2025Suspended2025-10-15
- Q2 FY2025Suspended2025-07-15
- Q1 FY2024Raised2024-04-15
- Q4 FY2024Maintained2024-13-15
- Q3 FY2024Lowered2024-10-15
- Q2 FY2024Lowered2024-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Brian LianCEO1 yr 10 mo19 callsCurrentSample
CEO since 2024 • 3/4 beats (75%) • last guidance cut Q2 FY2025
- Greg ZanteCFO1 yr 8 mo19 callsCurrentSample
CFO since 2024 • 2/4 beats (50%) • guidance suspended Q1 FY2025
- Marianna ManciniCOO1 yr 5 mo1 callCurrentSample
COO since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2025
- Neil William AubuchonChief Commercial Officer5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance cut Q2 FY2025
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for VKTX.
$ curl https://api.spokenalpha.com/v1/companies/VKTXFAQ
Frequently asked about VKTX
Where can I find Viking Therapeutics, Inc.'s (VKTX) earnings call transcripts?
Spoken Alpha indexes VKTX's earnings call transcripts at https://spokenalpha.com/companies/VKTX. Each call links to attributed speakers and parsed analyst Q&A. Viking Therapeutics, Inc.'s own investor relations page is at https://ir.vikingtherapeutics.com/.
When was Viking Therapeutics, Inc.'s most recent earnings call?
Viking Therapeutics, Inc. (VKTX) held its most recent earnings call on 2026-02-11, covering fiscal Q4 2025.
What sector is VKTX in?
Viking Therapeutics, Inc. (VKTX) operates in the Healthcare sector (Biotechnology industry).